- Glucagon-like peptide-1 (GLP-1) agonist medications have become increasingly popular over the last year.
- Previous research has revealed both potential positive and negative health effects when using GLP-1 agonist medications to bind and activate the GLP-1 receptor.
- Researchers from Boston Children’s Hospital have found that blocking, rather than activating, the GLP-1 receptor triggers the body’s innate defensive immune response to the development of colorectal cancer via a mouse model….
Read the full article here